Sanofi acquires Vigil Neuroscience to strengthen its Alzheimer's research

Sanofi announced the acquisition of Vigil Neuroscience to expand its portfolio of neurology treatments, particularly for Alzheimer's disease. This acquisition includes VG-3927, an investigational drug currently in clinical trials. VG-3927 aims to improve neuroprotective function in Alzheimer's disease by activating TREM2, which could offer new treatment options for these patients.

The $470 million deal will allow Sanofi to own all of Vigil's shares and includes a conditional earn-out payment. The companies expect to close the acquisition by the third quarter of 2025.